Amgen
Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours
June 4, 2019Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS
Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …
Top Ten most popular articles on Pharmafile.com this week
May 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
Amgen agrees to buy Nuevolution for $167 million
May 22, 2019Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …
FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients
April 10, 2019Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …
Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds
April 8, 2019Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data
A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …
Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron
February 26, 2019Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma
Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …
China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk
January 25, 2019Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke
Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …
Amgen and UCB’s Evenity approved in Japan for osteoporosis
January 9, 2019Research and Development, Sales and Marketing Amgen, Japan, UCB Pharma, osteoporosis, pharma
Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval …
Amgen donate $2m towards increasing diversity in clinical trials
December 12, 2018Research and Development Amgen, USA, clinical trials, diversity, donation
American multinational Amgen has teamed up with the Lazarex Cancer Foundation in support of an initiative aimed at increasing access …
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018
December 5, 2018Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …
Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz
November 27, 2018Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma
The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …
Mundipharma’s Neulasta biosimilar approved in EU
November 26, 2018Sales and Marketing Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma
Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European …
GSK named third best UK workplace
October 22, 2018Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work
British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …
Samsung and Bioepis launch third Humira biosimilar in Europe
October 17, 2018Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …
Amgen launches first biosimilar of best-selling Humira in Europe
October 16, 2018Manufacturing and Production, Sales and Marketing Amgen, Amgevita, Humira, biosimilar, pharma
Amgen has announced the launch of a proprietary biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) across all European markets, …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
